MiR-99a antitumor activity in human breast cancer cells through targeting of mTOR expression

PLoS ONE

Volumn 9, Issue 3, 2014, Pages

  Hu, Yu ^a   Zhu, Qin ^a   Tang, Lili ^a  

^a CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

INITIATION FACTOR 4E BINDING PROTEIN 1; MAMMALIAN TARGET OF RAPAMYCIN; MICRORNA; MICRORNA 99A; S6 KINASE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BREAST CANCER; CARCINOGENESIS; CELL DENSITY; CELL VIABILITY; CONTROLLED STUDY; DOWN REGULATION; FEMALE; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; LUCIFERASE ASSAY; MOUSE; NONHUMAN; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN TARGETING; RNA ISOLATION; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR GENE; TUMOR VOLUME; TUMOR XENOGRAFT; UPREGULATION;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BASE SEQUENCE; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL SURVIVAL; DOWN-REGULATION; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICE; MICRORNAS; MOLECULAR SEQUENCE DATA; PHOSPHOPROTEINS; PHOSPHORYLATION; RIBOSOMAL PROTEIN S6 KINASES, 70-KDA; SIGNAL TRANSDUCTION; TOR SERINE-THREONINE KINASES; UP-REGULATION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84898646416     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0092099     Document Type: Article

References (45)

1. Valencia-Sanchez MA, Liu J, Hannon GJ, Parker R. (2006) Control of translation and mRNA degradation by miRNAs and siRNAs. Genes Dev 20(5): 515-24 (Pubitemid 43345317)
2. Calin GA, Croce CM. (2006) MicroRNA signatures in human cancers. Nat Rev Cancer 6(11): 857-66 (Pubitemid 44629897)
3. He L, Thomson JM, Hemann MT, Hernando-Monge E, Mu D, et al. (2005) A microRNA polycistron as a potential human oncogene. Nature 435(7043): 828-33 (Pubitemid 40839734)
4. Esquela-Kerscher A, Slack FJ. (2006) Oncomirs - microRNAs with a role in cancer. Nat Rev Cancer 6(4): 259-69
5. Wang B, Wang H, Yang Z. (2012) MiR-122 inhibits cell proliferation and tumorigenesis of breast cancer by targeting IGF1R. PLoS One 7(10): e47053
6. Shimono Y, Zabala M, Cho RW, Lobo N, Dalerba P, et al. (2009) Downregulation of miRNA-200c links breast cancer stem cells with normal stem cells. Cell 138(3): 592-603
7. Ma L, Teruya-Feldstein J, Weinberg RA. (2007) Tumour invasion and metastasis initiated by microRNA-10b in breast cancer. Nature 449(7163): 682-8 (Pubitemid 47552092)
8. Sun J, Chen Z, Tan X, Zhou F, Tan F, et al. (2013) MicroRNA-99a/100 promotes apoptosis by targeting mTOR in human esophageal squamous cell carcinoma. Medical oncology (Northwood, London, England) 30(1): 411
9. Cui L, Zhou H, Zhao H, Zhou Y, Xu R, et al. (2012) MicroRNA-99a induces G1-phase cell cycle arrest and suppresses tumorigenicity in renal cell carcinoma. BMC Cancer 12: 546
10. Turcatel G, Rubin N, El-Hashash A, Warburton D. (2012) MIR-99a and MIR- 99b modulate TGF-beta induced epithelial to mesenchymal plasticity in normal murine mammary gland cells. PLoS One 7(1): e31032
11. Li D, Liu X, Lin L, Hou J, Li N, et al. (2011) MicroRNA-99a inhibits hepatocellular carcinoma growth and correlates with prognosis of patients with hepatocellular carcinoma. J Biol Chem 286(42): 36677-85
12. Sun D, Lee YS, Malhotra A, Kim HK, Matecic M, et al. (2011) miR-99 family of MicroRNAs suppresses the expression of prostate-specific antigen and prostate cancer cell proliferation. Cancer Res 71(4): 1313-24
13. Zhou J, Song T, Gong S, Zhong M, Su G. (2010) microRNA regulation of the expression of the estrogen receptor in endometrial cancer. Mol Med Rep 3(3): 387-92
14. Chen Z, Jin Y, Yu D, Wang A, Mahjabeen I, et al. (2012) Down-regulation of the microRNA-99 family members in head and neck squamous cell carcinoma. Oral Oncol 48(8): 686-91
15. Telford WG, King LE, Fraker PJ. (1992) Comparative evaluation of several DNA binding dyes in the detection of apoptosis-Associated chromatin degradation by flow cytometry. Cytometry 13(2): 137-43
16. Kajstura M, Halicka HD, Pryjma J, Darzynkiewicz Z. (2007) Discontinuous fragmentation of nuclear DNA during apoptosis revealed by discrete ''sub-G1'' peaks on DNA content histograms. Cytometry A 71(3): 125-31 (Pubitemid 46355337)
17. Oneyama C, Ikeda J, Okuzaki D, Suzuki K, Kanou T, et al. (2011) MicroRNAmediated downregulation of mTOR/FGFR3 controls tumor growth induced by Src-related oncogenic pathways. Oncogene 30(32): 3489-501
18. Nam EJ, Yoon H, Kim SW, Kin H, Kin YT, et al. (2008) MicroRNA expression profiles in serous ovarian carcinoma. Clin Cancer Res 14(9): 2690-5
19. Nagayama K, Kohno T, Sato M, Arai Y, Minna JD, et al. (2007) Homozygous deletion scanning of the lung cancer genome at a 100-kb resolution. Genes Chromosomes Cancer 46(11): 1000-10 (Pubitemid 47505213)
20. Wong TS, Liu XB, Wong BY, Ng RW, Yuen AP, et al. (2008) Mature miR-184 as Potential Oncogenic microRNA of Squamous Cell Carcinoma of Tongue. Clin Cancer Res 14(9): 2588-92
21. Oberg AL, French AJ, Sarver AL, Subramanian S, Morlan BW, et al. (2011) miRNA expression in colon polyps provides evidence for a multihit model of colon cancer. PLoS One 6(6): e20465
22. Li X, Zhang Y, Zhang H, Liu X, Gong T, et al. (2011) miRNA-223 promotes gastric cancer invasion and metastasis by targeting tumor suppressor EPB41L3. Mol Cancer Res 9(7): 824-33
23. Mueller AC, Sun D, Dutta A. (2013) The miR-99 family regulates the DNA damage response through its target SNF2H. Oncogene 32(9): 1164-72
24. Doghman M, El WA, Cardinaud B, Thomas E, Wang J, et al. (2010) Regulation of insulin-like growth factor-mammalian target of rapamycin signaling by microRNA in childhood adrenocortical tumors. Cancer Res 70(11): 4666-75
25. Hara K, Maruki Y, Long X, Yoshino K, Oshiro N, et al. (2002) Raptor, a binding partner of target of rapamycin (TOR), mediates TOR action. Cell 110(2): 177-89 (Pubitemid 34876546)
26. Kim DH, Sarbassov DD, Ali SM, King JE, Latek RR, et al. (2002) mTOR interacts with raptor to form a nutrient-sensitive complex that signals to the cell growth machinery. Cell 110(2): 163-75 (Pubitemid 34876545)
27. Kremer CL, Klein RR, Mendelson J, Browne W, Samadzedeh LK, et al. (2006) Expression of mTOR signaling pathway markers in prostate cancer progression. Prostate 66(11): 1203-12 (Pubitemid 44175342)
28. Ekman S, Wynes MW, Hirsch FR. (2012) The mTOR pathway in lung cancer and implications for therapy and biomarker analysis. J Thorac Oncol 7(6): 947-53
29. Martelli AM, Evangelisti C, Chiarini F, Grimaldi C, Manzoli L, et al. (2009) Targeting the PI3K/AKT/mTOR signaling network in acute myelogenous leukemia. Expert Opin Investig Drugs 18(9): 1333-49
30. Grabinski N, Ewald F, Hofmann BT, Staufer K, Schumacher U, et al. (2012) Combined targeting of AKT and mTOR synergistically inhibits proliferation of hepatocellular carcinoma cells. Mol Cancer 11: 85
31. Li M, Sun H, Song L, Gao X, Chang W, et al. (2012) Immunohistochemical expression of mTOR negatively correlates with PTEN expression in gastric carcinoma. Oncol Lett 4(6): 1213-1218
32. Lin HJ, Hsieh FC, Song H, Lin J. (2005) Elevated phosphorylation and activation of PDK-1/AKT pathway in human breast cancer. Br J Cancer 93(12): 1372-81 (Pubitemid 41752864)
33. Bose S, Chandran S, Mirocha JM, Bose N. (2006) The Akt pathway in human breast cancer: a tissue-Array-based analysis. Mod Pathol 19(2): 238-45 (Pubitemid 43117608)
34. Noh WC, Mondesire WH, Peng J, Jian W, Zhang H, et al. (2004) Determinants of rapamycin sensitivity in breast cancer cells. Clin Cancer Res 10(3): 1013-23 (Pubitemid 38198903)
35. Radimerski T, Montagne J, Rintelen F, Stocker H, van der kaay. (2002) dS6Kregulated cell growth is dPKB/dPI(3)K-independent, but requires dPDK1. Nat Cell Biol 4(3): 251-5 (Pubitemid 34218200)
36. Jefferies HB, Fumagalli S, Dennis PB, Reinhard C, Pearson RB, et al. (1997) Rapamycin suppresses 59TOP mRNA translation through inhibition of p70s6k. EMBO J 16(12): 3693-704 (Pubitemid 27250062)
37. Montagne J, Stewart MJ, Stocker H, Hafen E, Kozma SC, et al. (1999) Drosophila S6 kinase: a regulator of cell size. Science (New York, N.Y.) 285(5436): 2126-9 (Pubitemid 29451430)
38. Gera JF, Mellinghoff IK, Shi Y, Rettig MB, Tran C, et al. (2004) AKT activity determines sensitivity to mammalian target of rapamycin (mTOR) inhibitors by regulating cyclin D1 and c-myc expression. J Biol Chem 279(4): 2737-46 (Pubitemid 38114263)
39. Hidalgo M, Rowinsky EK. (2000) The rapamycin-sensitive signal transduction pathway as a target for cancer therapy. Oncogene 19(56): 6680-6 (Pubitemid 32197708)
40. Fingar DC, Richardson CJ, Tee AR, Cheatham L, Tsou C, et al. (2004) mTOR controls cell cycle progression through its cell growth effectors S6K1 and 4EBP1/eukaryotic translation initiation factor 4E. Mol Cell Biol 24(1): 200-16 (Pubitemid 38010048)
41. De Benedetti A, Graff JR. (2004) eIF-4E expression and its role in malignancies and metastases. Oncogene 23(18): 3189-99 (Pubitemid 38638830)
42. Soni A, Akcakanat A, Singh G, Luyimbazi D, Zheng Y, et al. (2008) eIF4E knockdown decreases breast cancer cell growth without activating Akt signaling. Mol Cancer Ther 7(7): 1782-8
43. Jastrzebski K, Hannan KM, Tchoubrieva EB, Hannan RD, Pearson RB. (2007) Coordinate regulation of ribosome biogenesis and function by the ribosomal protein S6 kinase, a key mediator of mTOR function. Growth factors (Chur, Switzerland) 25(4): 209-26
44. Heinonen H, Nieminen A, Saarela M, Kallioniemi A, Klefstrom J, et al. (2008) Deciphering downstream gene targets of PI3K/mTOR/p70S6K pathway in breast cancer. BMC Genomics 9: 348
45. Rojo F, Najera L, Lirola J, Jimenez J, Guzman M, et al. (2007) 4E-binding protein 1, a cell signaling hallmark in breast cancer that correlates with pathologic grade and prognosis. Clin Cancer Res 13(1): 81-9 (Pubitemid 46121856)